Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Signal transduction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Signal transduction. Displaying page 1 of 1.
    EudraCT Number: 2013-003791-12 Sponsor Protocol Number: 12345 Start Date*: 2013-10-30
    Sponsor Name:Helsinki University
    Full Title: SIGNAL TRANSDUCTION IN NAFLD
    Medical condition: No significant disease other than obesity/type 2 diabetes/hypertension/NAFLD
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001031-22 Sponsor Protocol Number: CCR2749 Start Date*: 2007-12-18
    Sponsor Name:Institute of Cancer Research
    Full Title: The Potentiation of Efficacy of Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC) by Inhibition of Akt Activation
    Medical condition: Non-small-cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011904-47 Sponsor Protocol Number: SoraDox2009 Start Date*: 2010-11-18
    Sponsor Name:Ethik-Kommission der Medizinischen Fakultät der Martin-Luther-Universität Halle Wittenberg
    Full Title: Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial
    Medical condition: Advanced hepatocellular carcinoma (HCC) stage C (or better) according to BCLC classification restricted to Child-Pugh class A/B (5-7 points).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002082-38 Sponsor Protocol Number: RG_11-123 Start Date*: 2012-04-16
    Sponsor Name:University of Birmingham
    Full Title: A study of the effects of Simvastatin on neutrophil function in elderly subjects
    Medical condition: We are investigating the effects of Simvastatin 80mg on neutrophil function (using in vitro studies of neutrophil function), in healthy elderly subjects as there is evidence to suggest that Simvast...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004750-24 Sponsor Protocol Number: 2013003 Start Date*: 2014-03-17
    Sponsor Name:Rode Kruis Ziekenhuis
    Full Title: Omega-3 fatty acids in bariatric gastric bypass surgery: effects on liver volume, immune response and erythrocyte function
    Medical condition: Patients qualified for bariatric surgery
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10068900 Bariatric surgery LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005091-36 Sponsor Protocol Number: 2020-005091-36 Start Date*: 2021-08-30
    Sponsor Name:Stichting Catharina Hospital
    Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    Population Age: Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005096-42 Sponsor Protocol Number: BO18279 Start Date*: 2005-06-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II marker identification trial for Tarceva in second line NSCLC patients
    Medical condition: Advanced (stage IIIb and IV) non small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) EE (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007167-16 Sponsor Protocol Number: CA163-196 Start Date*: 2009-09-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who H...
    Medical condition: Advanced, recurrent or metastatic endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014745 Endometrial carcinoma metastatic LLT
    9.1 10014747 Endometrial carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) IT (Prematurely Ended) ES (Temporarily Halted) FR (Completed) SE (Completed) GR (Completed) DK (Completed) HU (Completed) FI (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002538-20 Sponsor Protocol Number: EORTC 62027 Start Date*: 2006-02-24
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFib...
    Medical condition: Soft tissue sarcomas are a family of malignant diseases originating from mesenchymal cells. Two types of theses sarcomas, dermatofibrosarcoma protuberans (DFSP) and giant cell fibriblastoma(GCF), a...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057070 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001382-40 Sponsor Protocol Number: Metform01 Start Date*: 2011-09-09
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study
    Medical condition: Endometrial carcinoma or hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006161-84 Sponsor Protocol Number: Version 2.1 Start Date*: 2009-06-17
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: ARTiST - Aromasin Randomised Trial +/- Sutent as neoadjuvant Therapy for post-menopausal women with breast cancer.
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021944 Infiltrating ductal breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004562-40 Sponsor Protocol Number: GOG-0146Q Start Date*: 2008-01-14
    Sponsor Name:Gynecologic Oncology Group
    Full Title: A PHASE II EVALUATION OF TOPOTECAN ADMINISTERED WEEKLY IN THE TREATMENT OF RECURRENT PLATINUM-SENSITIVE OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Medical condition: Patients with recurrent ovarian, fallopian tube, or primary peritoneal cancers.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002109-38 Sponsor Protocol Number: AV-951-08-104 Start Date*: Information not available in EudraCT
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2a, Open-Label, Multi-Center Study of AV-951 in Combination with Paclitaxel in Subjects with Advanced or Metastatic Breast Cancer
    Medical condition: Advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015082-31 Sponsor Protocol Number: M10-757 Start Date*: 2010-04-07
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer
    Medical condition: Recurrent high grade serous ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001971-30 Sponsor Protocol Number: AP23573-08-207 Start Date*: 2008-11-10
    Sponsor Name:Merck & Co, Inc.
    Full Title: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000299-33 Sponsor Protocol Number: AGO-GYN8 Start Date*: Information not available in EudraCT
    Sponsor Name:AGO Research GmbH
    Full Title: Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma
    Medical condition: platinum-refractory ovarian carcinoma or advanced endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001040-23 Sponsor Protocol Number: TranspoCART19 Start Date*: 2023-03-15
    Sponsor Name:Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL
    Full Title: Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric a...
    Medical condition: Relapsed or refractory B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003900 B-cell lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002524-34 Sponsor Protocol Number: 011941 Start Date*: 2006-02-01
    Sponsor Name:BAYER Healthcare AG
    Full Title: An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) ES (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005235-14 Sponsor Protocol Number: A7471028 Start Date*: 2009-01-30
    Sponsor Name:Pfizer, S.A.
    Full Title: Ensayo en fase 2 aleatorizado de PF-00299804 frente a erlotinib para el tratamiento del cáncer de pulmón no microcítico avanzado tras el fracaso de al menos una pauta de quimioterapia previa A RAN...
    Medical condition: Cáncer de pulmón no microcítico Non-Small cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 22:06:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA